Skip to main content
    M

    Moderna Inc (MRNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $215.27
    -8.10 (-3.63%)

    Market Cap: $90.38B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Moderna Inc (MRNA) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Moderna (MRNA) to earn -$7.37 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.41B. Of 23 analysts, 4 rate the stock Buy or Strong Buy, 15 Hold and 4 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 4 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 23 ratings average 3.04, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 17% of the ratings.

    RatingAnalystsShare
    Strong Buy14.3%
    Buy313.0%
    Hold1565.2%
    Sell28.7%
    Strong Sell28.7%
    Consensus
    Hold
    Total analysts
    23

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 10.8%.

    Fiscal year ending Dec 31, 2026
    -$7.37
    EPS consensus, revenue $2.41B
    Fiscal year ending Dec 31, 2027
    -$4.34
    EPS consensus, revenue $2.67B
    Next report
    Feb 11, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$7.37-$9.06 to -$4.7719$2.41B$2.13B to $3.17B17
    Dec 31, 2027-$4.34-$5.96 to -$2.1220$2.67B$2.10B to $3.53B21

    Quarterly Estimates

    The EPS consensus rises from -$2.39 for the quarter ending Dec 31, 2026 to -$1.65 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$2.39-$4.20 to -$1.7820$556.23M$458.64M to $674.23M18
    Mar 31, 2027-$1.65-$2.19 to -$0.936$281.41M$77.00M to $462.00M5

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 9 upward and 8 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202644
    Fiscal year ending Dec 31, 202753
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$8.58.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$7.37-$8.49-$8.39-$8.38-$8.58N/A
    Fiscal year ending Dec 31, 2027-$4.34-$4.90-$4.78-$4.79-$4.91N/A
    Quarter ending Mar 31, 2027-$1.65-$1.85-$1.85-$1.85-$1.85N/A

    Frequently Asked Questions About MRNA

    What is the MRNA stock forecast?

    Consensus analyst estimates put Moderna's EPS at -$7.37 for the fiscal year ending Dec 31, 2026, on revenue of $2.41B. The consensus rating from 23 analysts is Hold.

    How do analysts rate MRNA stock?

    Of 23 analysts covering Moderna, 1 rates it Strong Buy, 3 Buy, 15 Hold, 2 Sell and 2 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from MRNA next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$7.37, with estimates from -$9.06 to -$4.77 from 19 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.34, with estimates from -$5.96 to -$2.12 from 20 analysts.

    What revenue do analysts expect from Moderna next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.41B, with estimates from $2.13B to $3.17B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $2.67B, with estimates from $2.10B to $3.53B.

    How many analysts cover MRNA?

    23 analysts rate Moderna stock, and 19 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.